PCN28 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB-CHOP VS. CHOP ON NON-HODGKIN LYMPHOMA PATIENTS IN THE MEXICAN CONTEXT  by Cortina, D et al.
adherence various. This original approach could be useful to
perform budget impact studies before implementing large public
health screening programs.
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OBJECTIVE: The American Association for the Study of Liver
Diseases 2005 practice guidelines recommended that various
groups at different levels of risk to hepatocellular carcinoma
(HCC) undergo surveillance. This study aimed to assess which
high risk group had the lowest incremental cost-effectiveness
ratio (ICER) for the HCC screening program from the insurer’s
perspective. METHODS: The high risk subjects were identiﬁed
from the communities with high prevalence of hepatitis viral
infection and classiﬁed into three groups at different levels of
risk to HCC at the time of enrollment. The repeated ultrasound
screenings at an interval of three, six, and twelve months were
applied to cirrhosis group, early cirrhosis group, and no cir-
rhosis group, respectively. The Markov-based decision model
was constructed to simulate progression of HCC and to esti-
mate the ICER for each group over a time horizon of 50 years
or the subjects’ remaining life expectancy. Validity of the model
outcomes was examined against the health statistics. RESULTS:
The incremental ICER for the cirrhosis group, early cirrhosis
group, and no cirrhosis group were $1375, $816, and $861,
respectively. Among the three groups, the early cirrhosis group
had the highest incremental effect (3.41 years per person) and
the cirrhosis group had the largest incremental cost ($4247 per
person). It is noteworthy that when compared to the other two
groups, the cirrhosis group showed the lowest incremental
effect (2.03 year) and the highest incremental cost ($4247).
CONCLUSION: Screening the no cirrhosis group for HCC at a
12-month interval had the lowest incremental cost-effectiveness
ratio.
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OBJECTIVE: This study is intended to evaluate the costs derived
from the treatment of aggressive and indolent Non-Hodgkin
Lymphoma (NHL), in patients treated with R-CHOP vs. CHOP
in order to provide solid pharmacoeconomic arguments for
decision-makers in regards to a cost-effective therapy for patients
with NHL and hence have a more efﬁcient allocation of
resources. METHODS: A cost-effectiveness analysis model was
developed based on the efﬁcacy reports of the international lit-
erature in regards to treatment of NHL estimating the probabili-
ties of no remission or disease relapse and the costs of treatment
failure and those derived from salvage therapies used. This was
calculated in a time horizon of 3 years with a 5% discount rate,
based on public health care institutions perspective. RESULTS:
The results of the model using a cohort of 200 hypothetic NHL
patients, 100: aggressive-NHL and 100: indolent-NHL, in which
50% received treatment with R-CHOP and the other half
with CHOP showed that the use of Rituximab in addition to
the CHOP therapy in the case of patients with Aggressive
NHL represents savings per patient in compete remission of
USD$138,530.33. In the case of patients with Indolent NHL the
savings were USD$1,366,417.78. Both savings represents the
possibility to obtain 10 more patients in complete remission (3
and 7 respectively). CONCLUSION: The use of Rituximab in
addition to CHOP as ﬁrst line therapy for NHL is not only a
cost-effective intervention when compared to CHOP therapy
in the Mexican context, but, according to the results, it is
also a cost-saving intervention with an average saving of
USD$821,739.23.
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OBJECTIVE: The paper calculates regional generalized cost-
effectiveness estimates of screening, prevention, treatment and
combined interventions for cervical cancer. METHODS: Stan-
dardised WHO-CHOICE methodology was used. A cervical
cancer model was employed to provide estimates of screening,
vaccination and treatment effectiveness. Intervention effective-
ness was determined via a population state-transition model
(PopMod) that simulates the evolution of a sub-regional popu-
lation accounting for births, deaths and disease epidemiology.
Economic costs of procedures and treatment were estimated,
including programme overhead and training costs. RESULTS: In
regions characterised by high income, low mortality and high
existing treatment coverage, the addition of any screening pro-
gramme to the current high treatment levels is very cost effective.
However, based on projections of the future price per dose
(representing the economic costs of the vaccination excluding
monopolistic rents and vaccine development cost) vaccination is
the most cost-effective intervention. In regions characterized by
low income, low mortality and existing treatment coverage
around 50%, expanding treatment with or without combining it
with screening appears to be cost effective or very cost-effective.
Abandoning treatment in favour of screening in a no-treatment
scenario would not be cost effective. Vaccination is usually the
most cost-effective intervention, however in some regions one-off
PAP or VIA screening at age 40 are more cost-effective than other
interventions though less effective overall. In regions character-
ised by low income, high mortality and low treatment levels,
expanding treatment with or without adding screening would be
very cost-effective. One-off PAP or VIA screening at age 40 are
more cost-effective than other interventions though less effective
overall. CONCLUSION: From a cost-effectiveness perspective,
consideration should be given to implementing vaccination
(depending on cost per dose) and screening programmes on a
worldwide basis to reduce the burden of disease from cervical
cancer. Treatment should also be increased where coverage is
low.
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OBJECTIVE: Treatment options for the relatively small group
of patients resistant or intolerant to imatinib, a recommended
ﬁrst-line therapy for chronic myeloid leukemia (CML), include
nilotinib or dasatinib. Current data indicates that nilotinib and
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